semaglutide fda label warns about safety of 'off-brand' versions of Ozempic, Wegovy compounded semaglutide fda enforcement news

7 If a patient meets these criteria, it is recommended that the addition of an agent with evidence for cardiovascular or renal risk reduction be considered independent of the patients current A1C or A1C target

Hepatic Impairment The effect of hepatic impairment on the pharmacokinetics of insulin glargine products has not been studied

The clinical question is what to do about it: dose adjustment, titration change, lifestyle review, or sometimes a switch to a different molecule

Chondrosarcoma of bone

Clinical follow-up and lab reviews Regular reviews are standard for everyone using Wegovy, but people with kidney or liver disease are usually monitored more closely